Incyte has reported positive top line data from the pivotal Phase III frontMIND trial assessing the safety and efficacy of ...

A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...

Consolidating treatment to a single bispecific antibody for DLBCL and follicular lymphoma can improve operational efficiency ...

Incyte INCY announced positive top-line results from a late-stage lymphoma study of Monjuvi/Minjuvi (tafasitamab), a ...

Incyte recently reported positive topline results from its pivotal Phase 3 frontMIND trial, where adding tafasitamab (Monjuvi/Minjuvi) and lenalidomide to R-CHOP improved progression-free survival for ...

While multi-indication bispecific therapies are likely to expand in lymphoma, their use must remain driven by efficacy, with ...

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for ...

Incyte Corporation rated Buy on surging Hem/Onc growth, Monjuvi/Minjuvi catalysts, frontMIND data and strong cash. Click for ...

A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.

Diffuse large B-cell lymphoma (DLBCL) grows fast, so you usually start treatment right away. The type you get depends on your overall health and stage of your cancer. For DLBCL, most people have ...

Follow-up data from the EPCORE NHL-1 trial lend further support to the efficacy and safety of single-agent epcoritamab (Epkinly) in the treatment of relapsed/refractory diffuse large B-cell lymphoma ...

Researchers have identified four genetic subtypes of diffuse large B-cell lymphoma (DLBCL) that may explain why some patients respond to treatment and others don't and provide a path toward precision ...